Lorvotuzumab mertansine regulatory update

ImmunoGen received Orphan Drug designation in the U.S. for lorvotuzumab mertansine to treat small cell lung cancer (SCLC). In addition, the COMP of the European Medicines Agency (EMA) issued a positiv...